Recently, LNC received the 177Lu-LNC1004 Injection IND approval from the NMPA (National Medical Products Administration), and will conduct the Phase I clinical trial in the near future.

Before then, 177Lu-LNC1004 injection has also obtain the IND approval from the US FDA (Food and Drug Administration) and the Singapore HSA (Health Sciences Authority).

—— About 177Lu-LNC1004 injection ——

177Lu-LNC1004 injection is a FAP-targeted radionuclide therapeutic drug, registered as Class 1 chemical drugs, suitable for patients with Advanced FAP-Positive Solid Tumors. The targeting specificity of FAP enables the delivery of radionuclide Lu-177 to the lesion site. Lu-177 is a therapeutic nuclide with an average range of 670 μm in tissues due to its relatively low β-particle energy. It has a relatively less suppressive effect on the bone marrow, which can kill tumor cells in a safer and more effective way, to reduce side effects on the human body. Evans Blue (EB) moiety in LNC1004 can increase the tumor effective uptake, extend the treatment time window, and achieve standard or better treatment effects with a reduced amount of radioactive isotopes, thus, reduce patients’ treatment burden.

LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. Next, LNC will continue to rely on DC PHARMA's strong and sound production and research system for the entire nuclear medicine industry chain, strengthen innovation, providing precision diagnosis and therapeutic methods for cancer patients and promoting the development of nuclear medicine in the world.